SEC-sourced researchBeta
ENTA
ENANTA PHARMACEUTICALS INC
Company comparison ↗
Data passport
- CIK
- 0001177648
- Exchange
- Nasdaq
- Business activity
- — · SIC 2834
- Financial inputs
- 6/6
- Filing date
- Nov 19, 2025
- SEC registry record
- Operating company
Annual financial history
Up to three published annual periods. The chart shows financial statement amounts; missing observations are not connected. Each company chart uses its own scale; compare amounts in the table.
| Period end | Revenue | Filing date |
|---|---|---|
| September 2023 | 79,204,000.0000 | Nov 19, 2025 |
| September 2024 | 67,635,000.0000 | Nov 19, 2025 |
| September 2025 | 65,324,000.0000 | Nov 19, 2025 |
Annual periods · USD
| Period end | Revenue | Net income | Operating cash flow | Total assets | Total liabilities | Filing date |
|---|---|---|---|---|---|---|
| September 2025 | 65,324,000.0000 | -81,889,000.0000 | -19,272,000.0000 | 280,732,000.0000 | 216,015,000.0000 | Nov 19, 2025 |
| September 2024 | 67,635,000.0000 | -116,045,000.0000 | -78,764,000.0000 | 376,652,000.0000 | 247,838,000.0000 | Nov 19, 2025 |
| September 2023 | 79,204,000.0000 | -133,816,000.0000 | -103,154,000.0000 | — | — | Nov 19, 2025 |
Financial inputs behind the calculation
| Financial inputs | USD | Period end | Filing date | Form |
|---|---|---|---|---|
| RevenueRevenueFromContractWithCustomerExcludingAssessedTax | $65.32M | September 2025 | Nov 19, 2025 | 10-K |
| Previous period revenueRevenueFromContractWithCustomerExcludingAssessedTax | $67.64M | September 2024 | Nov 19, 2025 | 10-K |
| Net incomeNetIncomeLoss | -$81.89M | September 2025 | Nov 19, 2025 | 10-K |
| Operating cash flowNetCashProvidedByUsedInOperatingActivities | -$19.27M | September 2025 | Nov 19, 2025 | 10-K |
| Total assetsAssets | $280.73M | September 2025 | Nov 19, 2025 | 10-K |
| Total liabilitiesLiabilities | $216.02M | September 2025 | Nov 19, 2025 | 10-K |